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Complex genomes are more than just the sum of their 
genes,  but  are  rather  complex  regulatory  systems  in 
which the expression of each individual gene is a function 
of the activity of many other genes, so that the levels of 
their protein products are maintained within a narrow 
range. Such homeostasis favors the maintenance of the 
appropriate  stoichiometry  of  subunits  in  multiprotein 
complexes or of components in signal transduction path­
ways, and defines the ‘ground state’ of a cell [1]. In diploid 
genomes, both alleles of a gene are usually active and this 
‘double dose’ of each gene is figured into the equation. 
Thus, deviations from diploidy, such as the deletion or 
duplication of genes or of larger chromosomal fragments 
(aneuploidy),  unbalance  the  finely  tuned  expression  of 
the  genome.  Segmental  aneuploidies  of  this  kind  can 
arise from failed or faulty repair of chromosomal damage 
due  to  irradiation,  chemical  insult  or  perturbation  of 
replication,  or  from  illegitimate  recombination  during 
meiosis.  Loss  or  duplication  of  entire  chromosomes 
(monosomy or trisomy, respectively) can arise from non­
disjunction during cell division. Depending on the extent 
of  the  aneuploidy  and  on  the  genes  affected,  the  fine 
balance  of  trans­acting  factors  and  their  chromosomal 
binding sites that define the gene­expression system is 
disturbed,  and  the  fitness  of  the  cell  or  organism 
challenged.
Often, aneuploidies have been associated with a variety 
of  developmental  defects  and  malignant  aberrations, 
such  as  Down  syndrome  or  certain  breast  cancers 
(reviewed  in  [2,3]).  The  phenotypes  associated  with 
changes in gene copy number can not only be the result 
of the deregulation of the affected gene(s), but may also 
reflect trans­acting effects on other chromosomal loci or 
even  more  global  alterations  of  the  entire  regulatory 
system.  This  is  particularly  true  if  genes  coding  for 
regulatory  factors,  such  as  transcription  factors,  are 
affected (reviewed in [4,5]).
Strategies for re-balancing aneuploid genomes
Genome­wide studies in different organisms reveal that 
the expression of a substantial number of genes directly 
correlates with gene dose (the primary dosage effect) [6]. 
In  other  cases,  the  measured  expression  levels  do  not 
reflect the actual copy number, as compensatory mecha­
nisms  aimed  at  re­establishing  homeostasis  take  effect 
[4,5]. Imbalances due to aneuploidy may be compensated 
for at any step of gene expression from transcription to 
protein  stability.  Excess  subunits  of  multiprotein 
complexes that are not stabilized by appropriate inter­
actions  are  susceptible  to  degradation  (see  [1]  for  a 
discussion of compensation at the protein level). Dosage­
compensation mechanisms at the level of transcription 
are versatile, intricate, and in no instance are they fully 
understood.
In principle, three types of compensatory responses to 
aneuploidies  are  recognized:  buffering,  feedback,  and 
feed­forward, which may act individually or, more likely, 
in  combination  [7].  Oliver  and  colleagues  [7]  define 
buffering as ‘the passive absorption of gene dose pertur­
bations  by  inherent  system  properties’.  Currently,  the 
nature  of  this  general  or  ‘autosomal’  buffering  is  un­
known, but its existence can be deduced from comparing 
gene  expression  to  DNA  copy  number  in  healthy  and 
aneuploid  genomes  [8­11].  The  system  properties 
referred to by Oliver and colleagues can be considered as 
the sum of the biochemical equilibria of the system ‘living 
cell’, which are predicted to moderate the effect of the 
reduction of one component. Apparently, the deletion of 
one  gene  copy  (that  is,  a  twofold  reduction  in  gene 
expression)  can  be  partially  compensated  for  by 
increasing the steady­state mRNA levels originating from 
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Interestingly, Stenberg and colleagues [11] observed that 
buffering appears to compensate for deficiencies better 
than  for  gene  duplications,  which  leaves  open  the 
existence of a general sensor of monosomy that mediates 
the  effect.  A  general  buffering  will  also  ameliorate  the 
conse  quences  of  widespread  mono­allelic  gene  expres­
sion  due  to  parental  imprinting  (cases  where  a  single 
allele is expressed, depending on whether it is inherited 
from the father or mother) [12].
In contrast to the general and nonspecific buffering just 
described, a ‘feedback’ mechanism would be defined as 
gene­specific  ­  sensing  and  readjusting  the  levels  of 
specific molecules by appropriate, specific mechanisms. 
Finally, ‘feed­forward’ anticipates the deviation from the 
norm  and  hence  can  only  be  at  work  in  very  special 
circumstances. Prominent examples where feed­forward 
scenarios are applicable are the widely occurring mono­
somies in the sex chromosomes of heterogametic organ­
isms (for example, the XX/XY sex­chromosome system), 
which are present in each and every cell of the species.
In  contrast  to  aneuploidies  that  arise  spontaneously, 
these ‘natural’ monosomies and their associated dosage­
compensation mechanisms are the products of evolution. 
Research on dosage­compensation mechanisms associa­
ted  with  sex  chromosomes  continues  to  uncover  un­
expected complexities and intricacies. The somatic cells 
of the two sexes of the main model organisms of current 
research ­ mammals, nematode worms (Caenorhabditis 
elegans) and fruit flies (Drosophila melanogaster) ­ differ 
in  that  those  of  females  are  characterized  by  two  X 
chromosomes, while those of males have one X and one 
Y chromosome (mammals and Drosophila); or one sex 
(XX) is a hermaphrodite and the males have just a single 
X  and  no  Y  chromosome  (X0)  (C.  elegans)  [13]. 
Remarkably, different dosage­compensation strategies for 
balancing  gene  expression  from  the  X  chromosome 
between the sexes have evolved independently in these 
three cases (Figure 1), as we shall discuss in this article. 
There is increasing evidence that in all three cases, the 
transcription  of  most  genes  on  the  single  male  X 
chromosome  is  increased  roughly  twofold  [14­16].  In 
fruit  flies,  this  upregulation  of  the  X  chromosome  is 
limited to males. In mammals and worms, however, the X 
chromosomes appear to be also upregulated in the XX 
sex, which necessitates additional compensatory measures. 
In  female  mammals,  one  of  the  X  chromosomes  is 
globally silenced, whereas in hermaphrodite worms, gene 
expression on both X chromosomes is downregulated by 
about 50% (Figure 1). An emerging principle is that the 
net  fold­changes  of  dosage  compensation  are  not 
achieved  by  a  single  mechanism  (that  is,  there  is  no 
simple  switch  for  ‘twofold  up’),  but  by  integration  of 
activating and repressive cues, as discussed later.
In what follows we summarize recent insight into the 
dosage­compensation  mechanisms  of  the  XX/XY  sex 
chromosome  systems,  which  nicely  illustrate  the 
evolution of  global, genome­wide regulatory strategies. 
However,  compensation  systems  of  this  type  are  not 
absolutely  required  for  the  evolution  of  heterogametic 
sex. Birds, some reptiles, and some other species use the 
ZW/ZZ sex­chromosome system, which does not use the 
mechanism of chromosome­wide transcriptional regula­
tion to compensate for monosomy [17­19].
Dosage compensation of sex chromosomes reveals 
the balancing capacity of chromatin
The sex chromosomes of the XX/XY system are thought 
to have originated from two identical chromosomes in a 
slow process that was initiated by the appearance of a 
male­determining gene. In order to be effective, this gene 
should be propagated only in males, which was achieved 
by evolving a Y chromosome that was specifically propa­
gated through the male germline. The necessary suppres­
sion of recombination between this ‘neo­Y’ chromosome 
Figure 1. Schematic representation of different dosage-
compensation systems. (a) Drosophila melanogaster, (b) Homo 
sapiens, (c) Caenorhabditis elegans. Combinations of chromosomes 
in the diploid somatic cells of males and females are shown. The sex 
chromosomes are symbolized by the letters X and Y, autosomes as 
A. Dosage-compensated chromosomes are colored: red indicates 
activation, blue repression. The sizes of the As indicate the average 
expression level of an autosome in a diploid cell. The sizes of the 
X chromosomes reflect their activity state (see text). The arrows 
represent the activating and repressive factors that determine the 
activity of the corresponding sex chromosome. In Drosophila (a), 
the male X chromosome is transcriptionally activated twofold in the 
male to match the total level of expression from the two female X 
chromosomes. In mammals (b), X chromosomes are hypertranscribed 
in both sexes, and to equalize X-chromosomal gene expression 
between the sexes, one of the two X chromosomes is inactivated 
in females. In C. elegans (c), males do not have a Y chromosome (O 
indicates its absence) and XX individuals are hermaphrodites. Worms 
also overexpress X-linked genes in a sex-independent manner, 
as indicated by the red-colored Xs, but subsequently halve the 
expression levels of the genes from both X chromosomes in the 
hermaphrodite (indicated by the blue Xs) to equalize gene dosage 
between the sexes.
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Page 2 of 8and the corresponding sister chromosome (which would 
become the future ‘neo­X’) favored the accumulation of 
mutations,  deletions  and  transposon  insertions,  an 
erosive process that led to loss or severe degeneration of 
Y chromosomes [20­24]. The progressive erosion of the 
evolving  Y  left  many  X­chromosomal  genes  without  a 
corresponding  copy  on  the  Y  chromosome  (the  hemi­
zygous state). The initial consequences of gene loss on 
the  Y  chromosome  may  have  been  absorbed  by  the 
intrinsic  biochemical  buffering  properties  of  the  cell 
noted above [11]. However, when the majority of genes 
on  the  X  chromosome  lost  their  homologs  on  the  Y 
chromosome the co­evolution of regulatory processes to 
overcome  the  reduced  gene  dose  ­  that  is,  dosage­
compensation  systems  ­  increased  the  fitness  of  the 
organisms. These dosage­compensation systems are likely 
to originate in the male sex (XY or X0 in the examples 
discussed here), as it is in males that factors acting in a 
dose­dependent  manner  (such  as  transcription  factors, 
chromatin  constituents  and  components  of  signal­
transduction cascades) would become limiting [25,26].
A  logical  adaptation  to  ensure  the  survival  of  males 
would  be  the  increased  expression  of  X­chromosomal 
genes [6]. This intuitively obvious mechanism has long 
been  known  in  Drosophila.  Observing  the  specialized 
polytene chromosomes in larvae (which are composed of 
thousands of synapsed chromatids arising from repeated 
DNA  replication  without  chromosome  segregation), 
Mukherjee  and  Beermann  [27]  were  able  to  directly 
visualize  nascent  RNA  and  found  that  the  single  X 
chromosome in males gave rise to almost as much RNA 
as  two  autosomes.  Recent  genome­wide  expression 
analyses confirmed these early observations [28,29] and 
further genome­wide studies suggest that this mechanism 
may also operate in C. elegans and mammals [14­16]. For 
these species neither the mechanism of this chromosome­
wide regulation nor the factors involved are known.
For  Drosophila,  however,  thanks  to  decades  of  out­
standing  genetics  exploring  male­specific  lethality,  we 
know at least a few of the prominent players. Here, the 
twofold stimulation of transcription on the X chromo­
some  is  mediated  by  the  male­specific  assembly  of  a 
dosage­compensation complex (the Male­Specific­Lethal 
(MSL) complex), a ribonucleoprotein complex that asso­
ciates  almost  exclusively  with  the  X  chromosome 
(reviewed in [30]; Figure 2). Most subunits of the MSL 
complex are found in both sexes of Drosophila, except for 
the key protein MSL2 and the noncoding roX (RNA­on­
the­X) RNAs, which are only expressed in males (Figure 2), 
thus  leading  to  the  assembly  of  the  MSL  complex 
exclusively  in  male  cells.  The  MSL  complex  associates 
with the transcribed regions of target genes in a multi­
step process that has been reviewed elsewhere [31­33]. 
Key  to  the  stimulation  of  transcription  is  the 
MSL­complex subunit MOF (Males­absent­on­the­first; 
also known as KAT8, lysine acetyltransferase 8), a histone 
acetyltransferase  with  specificity  for  lysine  16  in  the 
amino­terminal tail of histone 4 (H4K16ac). Acetylation 
of this residue is known to reduce interactions between 
nearby  nucleosomes  and  leads  to  unfolding  of  nucleo­
somal fibers in vitro [34,35].
Whereas  the  action  of  the  dosage­compensation 
complex in Drosophila is limited to males, in C. elegans 
and  mammals  the  unknown  factors  that  stimulate  X­
chromosomal  transcription  appear  to  be  active  in  the 
hermaphrodite  and  the  female,  as  well  as  in  males.  If, 
however,  X  activation  re­balances  the  male  genome  in 
these species, it follows that in the XX sex, having two 
hyperactive  X  chromosomes  relative  to  the  autosomes 
must be suboptimal [36]. Consequently, further compen­
sation  is  needed.  Mammals  have  evolved  a  strategy  of 
inactivating one of the female X chromosomes to achieve 
a level of X­chromosome gene expression closely resemb­
ling that from the single X in males (reviewed in [37]; 
Figure  1b).  Which  X  is  inactivated  is  random,  and 
inactivation  starts  with  the  stable  transcription  of  the 
long, non­coding Xist (Xi­specific transcript) and RepA 
(repeat A) RNAs from a complex genetic region on the 
future  inactive  X  (Xi)  called  the  X­inactivation  center. 
Subsequently,  Xist  RNA  ­  possibly  in  complex  with 
undefined  protein  components  ­  spreads  to  coat  the 
entire Xi. Silencing involves the recruitment and action 
of  the  Polycomb  silencing  machinery  via  the  Xist  and 
RepA RNAs [38,39], followed by reinforcement through 
the incorporation of histone variants, removal of activat­
ing  histone  modifications  and  DNA  methylation  [37]. 
Remarkably,  the  independent  evolution  of  nematode 
worms arrived at a very different solution to the problem. 
C.  elegans  equalizes  the  gene  dose  by  halving  the 
expression levels of genes on both X chromosomes in the 
hermaphrodite,  using  a  large  dosage­compensation 
complex containing components of the meiotic/mitotic 
condensin. The involvement of condensins may point to 
regu  la  tion  at  the  level  of  chromatin  fiber  compaction 
([40]  and  references  therein).  The  scenario  shown 
schema  tically  in  Figure  1c  for  C.  elegans  suggests  that 
dosage compensation in this species involves a twofold 
increase in X­linked transcription in both sexes, which is 
opposed by a twofold repression in hermaphrodites. The 
underlying mechanisms are still mysterious.
This short summary of the three very different dosage­
compensation  systems  reveals  two  common  denomi­
nators.  First,  they  all  adapt  factors  and  mechanisms, 
which are already involved in other regulatory processes, 
for the compensation task by harnessing them in a new 
molecular  context.  Furthermore,  these  factors  are  all 
known for their roles in modulating chromatin structure. 
It seems that chromatin can adopt a variety of structures 
Prestel et al. Genome Biology 2010, 11:216 
http://genomebiology.com/2010/11/8/216
Page 3 of 8with graded activity states, which can be used either to 
completely switch off large chromosomal domains or to 
fine­tune transcription (either up or down) in the twofold 
range.  Dosage  compensation  therefore  integrates  with 
other aspects of chromatin organization. In Drosophila, 
the  male  X  chromosome  that  accumulates  the  H4K16 
acetylation mark is particularly sensitive to mutations in 
general chromatin organizers. Prominent among these is 
the zinc finger protein Su(var)3­7 (suppressor of varie­
gation  3­7),  a  heterochromatin  constituent  known  to 
bind HP1 (heterochromatin protein 1). Normal levels of 
Su(var)3­7 are required for proper dosage compensation 
and  to  ensure  the  selective  binding  of  the  dosage­
compensation  complex  to  the  X  chromosome  [41­43]. 
The  male  X  polytene  chromosome  bloats  when 
Su(var)3­7 levels are reduced and condenses when the 
protein  is  in  excess.  These  changes  in  chromatin 
condensation  depend  on  a  functional  dosage  compen­
sation  complex,  suggesting  that  the  MOF­catalyzed 
acetylation of histone 4, and subsequent unfolding effect 
of H4K16ac, is constrained by as yet unknown counter­
acting  factors  (Figure  3a),  conceivably  by  ones  that 
promote chromatin compaction.
Selective,  massive  unfolding  of  the  dosage­compen­
sated male X chromosome in Drosophila is also observed 
when  the  nucleosome  remodeling  factor  (NURF)  is 
inactivated  [44,45].  Nucleosome  remodeling  by  NURF 
may thus also serve to counteract excessive unfolding due 
to  H4K16  acetylation.  Tamkun  and  colleagues  [46] 
suggested  that  NURF  might  achieve  this  task  by 
maintaining sufficiently high histone H1 levels on the X 
chromosome. Clearly, the degree of chromatin compac­
tion  can  be  adjusted  by  integration  of  unfolding  and 
compacting factors.
Figure 2. The Drosophila melanogaster male dosage-compensation complex. The complex, called the MSL complex in Drosophila, consists 
of five proteins (MSL1, MSL2, MSL3, MOF, MLE) and two non-coding roX RNAs. The proteins, but not the roX RNAs, are evolutionarily conserved, 
as related proteins can be found in yeast and humans (for details see [30,68,69]). The box lists the conserved protein domains of the individual 
members of the Drosophila MSL complex and their identified functions for dosage compensation. MSL2 is the only male-specific protein subunit; all 
other subunits are present in both sexes. The two roX RNAs (see bottom of table) are also only expressed in males. The curved arrows symbolize the 
known enzymatic activities in the dosage-compensation complex. MLE is an RNA helicase that hydrolyzes ATP to effect conformational changes 
in DNA and RNA [70]. MOF is a lysine acetyltransferase with specificity for lysine 16 of histone H4. Abbreviations of the protein domains are: CXC, 
cysteine-rich domain; ZnF, zinc finger; PEHE, proline-glutamic acid-histidine-glutamic acid; HAT, histone acetyltransferase; MYST, MOZ (monocytic 
leukemia zinc finger protein), YBF2/SAS3 (something about silencing 3), SAS2 and TIP60 (60 kDa Tat-interactive protein); MRG, mortality factor on 
chromosome 4 related gene and DExH, aspartic acid-glutamic acid-x-histidine.
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Further analysis of the role of Drosophila MOF in dosage 
compensation suggests that it may affect gene expression 
by  modulating  the  productivity  of  the  transcription 
machinery in the chromatin context. Although MOF is 
able to acetylate non­histone substrates [47,48], its main 
substrate in the context of dosage compensation is the 
strategic  H4K16.  Biochemical  studies  showed  that  this 
modification  interferes  directly  with  the  folding  of  the 
nucleosomal  chain  into  30­nm  fibers  in  vitro  [35,49]. 
Accordingly,  H4K16  acetylation  by  MOF  has  the 
potential  to  counteract  chromatin­mediated  transcrip­
tional  repression  [50,51]  (Figure  3a).  In  the  simplest 
scenario, the only task of the MSL complex in Drosophila 
would be to enrich MOF on the X chromosome relative 
to the autosomes. However, studies of the effect of MOF 
in yeast or in a cell­free chromatin transcription system 
showed that H4K16 acetylation does not automatically 
increase transcription by twofold, but by many­fold [50]. 
This  strong  activation  potential  of  MOF  can  also  be 
visualized in Drosophila. We recently established Droso­
phila lines in which MOF is tethered to a β­galactosidase 
reporter gene engineered to reside on an autosome [51]. 
Sorting adult flies according to sex allowed comparison 
of  MOF­dependent  reporter  gene  stimulation  in  male 
flies,  where  MOF  is  part  of  the  dosage­compensation 
complex, and in females, where its molecular context was 
initially  unknown.  In  females,  MOF  recruitment 
stimulated transcription from a proximal promoter by an 
order  of  magnitude.  The  effect  faded  with  increasing 
distance between recruitment site and transcription start 
site and therefore appears to be related to local chromatin 
opening by promoter­bound co­activators.
By contrast, the molecular context of the MSL complex 
in males restricted the activation effect of MOF to the 
twofold range reminiscent of dosage compensation, and 
this effect was observable over a distance of 5 kb [51]. 
Notably, similar H4K16 acetylation levels accompanied 
the very different activation modes in the two sexes. So it 
seems that the activation potential of H4K16 acetylation 
revealed  in  females  is  constrained  in  males.  Ectopic 
assembly of the MSL complex in females by expression of 
MSL2  constrained  the  strong  activation  to  a  twofold 
range [51]. We concluded from these and further studies 
that  the  Drosophila  dosage­compensation  complex 
achieves  a  twofold  activation  of  transcription  by 
integrating activating and repressive principles [51].
MOF serves as an example of the principle that dosage 
compensation employs chromatin modifiers that are also 
functional in other contexts. MOF is expressed at only 
slightly lower levels in females than in males, and it also 
resides in at least one other complex in addition to the 
MSL  complex.  Mendjan  et  al.  [52]  first  reported  the 
existence of an alternative complex (the NSL complex, 
for  ‘Non­Specific­Lethal’)  in  mixed­sex  embryos  and 
male cells of Drosophila, which contained a number of 
poorly  characterized  nuclear  proteins  and  two 
Figure 3. Possible mechanisms for dosage compensation. 
(a) The twofold activation of the single male X chromosome in 
Drosophila could be achieved by a large, MOF-dependent activation 
of transcription through H4K16 acetylation and its counteraction 
by yet unknown factors, mediated by the dosage-compensation 
complex in males [51]. In (a,b), transcriptional level 1 refers to the 
normal regulated level of transcription from a single uncompensated 
X chromosome in females. (b) Furthermore, the twofold activation 
of the male X chromosome could be achieved by a combination 
of mechanisms: a general buffering/feedback component and a 
dedicated feed-forward mechanism (dosage compensation as 
suggested in (a)) [7]. The effects of these two processes could add 
up to the expected twofold compensation required to equalize 
the expression of X-linked genes between the sexes. (c) Precise 
transcription levels could result from negotiation between a number 
of activating and repressive factors (up and down arrows). In this 
instance, transcriptional level 1 refers to a ‘basal’ transcription state. 
This hypothetical model assumes that additional factors beyond 
those mentioned in (a) and (b) contribute to final transcription 
levels, such as male-enriched protein kinases, heterochromatin 
components, chromatin remodelers, and others (for details, see text).
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Page 5 of 8components  of  nuclear  pores  [52].  The  closely  related 
MOF­MBD­R2  complex,  purified  by  us  from  female 
Drosophila cells [51], shares several prominent compo­
nents with the NSL complex, including WDS (Will Die 
Slowly, a homolog of mammalian WDR5 (WD repeat­
containing protein 5), dMCRS2 (microspherule protein 1), 
a forkhead­associated domain protein, and MBD­R2 (an 
uncharacterized protein harboring similarity to methyl­
CpG­binding  domains)  [53].  In  contrast  to  the  NSL 
complex, the MOF­MBD­R2 complex does not contain 
nuclear pore components [51].
The evidence so far suggests that the MOF­MBD­R2 
complex provides the molecular context for the strong 
activation elicited by MOF in females. Globally, MOF co­
localizes with MBD­R2 to active genes with enrichment 
towards their 5’ ends on all chromosomes in male and 
females, except for the male X chromosome (Figure 4). In 
male  Drosophila  cells,  MOF  is  enriched  on  the  X 
chromo  some,  where  it  co­localizes  with  MSL­complex 
components (such as MSL1) with a bias towards the 3’ 
end (Figure 4). In male Drosophila cells, MOF apparently 
distributes  dynamically  between  the  two  complexes. 
Ectopic expression of MSL2 in female cells, which leads 
to  assembly  of  a  dosage­compensation  complex,  re­
localizes MOF from the autosomes to the X chromosome 
and from the 5’ end to the 3’ end of transcribed genes. 
The 3’ enrichment suggests that dosage compensation in 
Drosophila  may  act  at  the  level  of  transcription 
elongation [54,55].
The earlier notion that MOF, a global activator of trans­
cription, was harnessed to balance the X­chromosomal 
monosomy in male Drosophila is supported by the fact 
that  the  H4K16­specific  acetyltransferase  activity  has 
been conserved during evolution, although its biological 
function has not [56,57]. MOF (KAT8) is the best­studied 
member of the evolutionarily conserved family of MYST 
acetyltransferases (MOZ (monocytic leukemia zinc finger 
protein),  YBF2/SAS3  (something  about  silencing  3), 
SAS2 and TIP60 (60 kDa Tat­interactive protein)). To the 
best of our knowledge, mammalian MOF is not involved 
in dosage compensation, but in regulating gene expres­
sion in more specific ways and in maintaining genome 
stability. Knock­down of human MOF impairs the signal­
ing of DNA damage via the ATM pathway in response to 
double­strand breaks, causing increased cell death and a 
loss  of  the  cell­cycle  checkpoint  response  [58].  Mouse 
MOF is essential for oogenesis and embryogenesis [59]. 
Loss of H4K16ac is a cancer hallmark [60] and MOF is 
deregulated in a number of diseases [61,62].
As in Drosophila, mammalian MOF resides in several 
distinct complexes. These include the MOF­MLL1­NSL 
complex, which is required for the expression of the Hox 
9a gene [63]; a complex containing the homologs of the 
Drosophila MSL3 and MSL1 that contributes to global 
H4K16 acetylation [64,65]; and a complex most closely 
related to the Drosophila NSL complex [52], containing 
human NSL1 (MSL1v1) and PHF20 (PHD finger protein 
20, the homolog of MBD­R2), in addition to other NSL 
protein homologs. This complex has attracted particular 
attention as it is not only responsible for the majority of 
H4K16ac in human cells [66], but also acetylates p53 at 
lysine 120 (K120) [66,67]. p53 in which K120 is mutated 
can no longer trigger the apoptotic pathway, yet its role 
in  the  cell­cycle  checkpoint  is  not  impaired.  Evidently, 
the  substrate  specificity  of  human  MOF  and  the 
physiological processes in which it is involved are largely 
determined by the molecular context of the acetyl  trans­
ferase,  defined  by  the  composition  of  the  different 
complexes. In Drosophila, however, one of the complexes 
has  been  adapted  to  serve  the  goal  of  balancing  the 
genome for dosage compensation.
Negotiation for small effects
Although  the  mechanisms  through  which  aneuploidies 
are  compensated  for  are  still  mysterious,  a  number  of 
overarching principles have emerged during recent years, 
Figure 4. Schematic representation of the distribution of the 
key regulators of dosage compensation on a target gene in 
Drosophila. The gene is depicted as a gray bar at the top of the 
figure, with the arrow representing the transcription start site. The 
figure is based on genome-wide binding studies of MOF, MBD-R2 
and MSL1. The upper panel shows that MBD-R2 is enriched at 
promoters (5’) on all chromosomes in both sexes, underscoring its 
function as a general transcriptional facilitator. MOF co-localizes with 
the promoter peak of MBD-R2 on all chromosomes except for the 
male X chromosome, where it is more enriched towards the 3’ end 
of the target gene as a result of its association with the dosage-
compensation complex (bottom panel). The MSL1 profile serves as a 
marker for the presence of the dosage-compensation complex [51]. 
For details see text.
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somies. First, there is no simple switch for ‘two­fold up’ 
or ‘two­fold down’. Optimal expression levels are nego­
tiated  by  opposing  principles.  The  X­chromosomal 
expres  sion  in  hermaphrodite  C.  elegans  results  from 
integration of a global, twofold increase in expression in 
both sexes and a different counteracting hermaphrodite­
specific  principle,  which  halves  the  expression  again 
(Figure 1c).
The first genome­wide comparison of copy number and 
transcription  in  Drosophila  revealed  that  a  local  or 
chromosomal  hemizygosity  is  compensated  for  by  the 
integration  of  at  least  two  different  mechanisms:  an 
approximately 1.5­fold compensation can be attributed to 
general  buffering  or  feedback  effects,  whereas  the 
remain  ing compensation is contributed by the evolution 
of  a  feed­forward  mechanism  involving  a  dedicated 
dosage­compensation complex [7] (Figure 3b). Further­
more,  the  twofold  activation  in  male  Drosophila  is  a 
composite of a much larger stimulation, which is opposed 
by a repressive principle (Figure 3a). We therefore envis­
age that adjustment of the optimal gene expression levels 
may be a consequence of negotiation between a number 
of  counteracting  activating  and  repressing  principles 
(Figure  3c).  The  complex  and  layered  organization  of 
chromatin appears to us as an advanced equalizer with 
many levers to allow optimal tuning of the transcription 
melody.
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